Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2014

View Archived Issues

Development of novel potent oxytocin receptor agonists to correct aberrant preterm lactation

Burnet Institute and Artes Biotechnology to develop new type of malaria vaccine

Pfizer reflects on achievements of second quarter 2014

AstraZeneca to acquire Almirall's respiratory business

AstraZeneca and Kyowa Hakko Kirin form clinical immuno-oncology collaboration

Roche and AmorChem collaborate in myotonic muscular dystrophy 1

Zealand Pharma and Boehringer Ingelheim collaborate in cardiometabolic disease

Immune Pharmaceuticals initiates phase II trial of bertilimumab in bullous pemphigoid

Novel Nrf2 pathway activator tested in animal model for treatment of ischemia-reperfusion injury

Piramal Enterprises designs novel agents for cancer

New compounds for bacterial infections disclosed by Actelion Pharmaceuticals

Promising preclinical results with anti-CD154 antibody BMS-986004 in kidney transplant models

Merck KGaA patents new piperidinylcarbazole derivatives for malaria

Gilead Sciences synthesizes novel antiretrovirals

Aurigene Discovery Technologies divulges novel BTK inhibitors

Phase II efficacy, safety and favorable pharmacometrics of TOL-101

Stivarga approved in the E.U. for gastrointestinal stromal tumors

Regeneron and Sanofi report topline data from nine phase III trials of alirocumab

Baxter divests commercial vaccines business to Pfizer

Incyte and Genzyme to evaluate combination of two novel cancer immunotherapies

New start-up Emulate to commercialize Wyss Institute's Organs-on-Chips technology

Amgen reveals milestones of second quarter 2014

Glide Pharmaceutical licenses rights from FScan to prostate cancer diagnostic technology

Angelini to commercialize dalbavancin in select European countries

Evotec identifies novel targets in Alzheimer's disease collaboration with Janssen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...